» Authors » J A Engelman

J A Engelman

Explore the profile of J A Engelman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 32
Citations 2826
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Hata A, Rowley S, Archibald H, Gomez-Caraballo M, Siddiqui F, Ji F, et al.
Oncogene . 2017 Aug; 36(47):6581-6591. PMID: 28783173
There are currently no effective targeted therapies for KRAS mutant cancers. Therapeutic strategies that combine MEK inhibitors with agents that target apoptotic pathways may be a promising therapeutic approach. We...
2.
Shaw A, Varghese A, Solomon B, Costa D, Novello S, Mino-Kenudson M, et al.
Ann Oncol . 2012 Aug; 24(1):59-66. PMID: 22887466
Background: Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) is highly responsive to crizotinib. To determine whether ALK-positive NSCLC is also sensitive to pemetrexed, we retrospectively evaluated progression-free survival (PFS)...
3.
Sequist L, Heist R, Shaw A, Fidias P, Rosovsky R, Temel J, et al.
Ann Oncol . 2011 Nov; 22(12):2616-2624. PMID: 22071650
Background: Personalizing non-small-cell lung cancer (NSCLC) therapy toward oncogene addicted pathway inhibition is effective. Hence, the ability to determine a more comprehensive genotype for each case is becoming essential to...
4.
Baba Y, Nosho K, Shima K, Meyerhardt J, Chan A, Engelman J, et al.
Br J Cancer . 2010 Sep; 103(7):1025-33. PMID: 20808308
Background: AMP-activated protein kinase (AMPK, PRKA) has central roles in cellular metabolic sensing and energy balance homeostasis, and interacts with various pathways (e.g., TP53 (p53), FASN, MTOR and MAPK3/1 (ERK))....
5.
Chakrabarty A, Rexer B, Wang S, Cook R, Engelman J, Arteaga C
Oncogene . 2010 Jun; 29(37):5193-203. PMID: 20581867
Hyperactivation of phosphatidylinositol-3 kinase (PI3K) can occur as a result of somatic mutations in PIK3CA, the gene encoding the p110α subunit of PI3K. The HER2 oncogene is amplified in 25%...
6.
Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, et al.
Oncogene . 2010 Feb; 29(16):2346-56. PMID: 20118985
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib are effective therapies against mutant non-small cell lung cancers (NSCLCs). Treatment is limited by the development of resistance in...
7.
Razani B, Engelman J, Wang X, Schubert W, Zhang X, Marks C, et al.
J Biol Chem . 2001 Jul; 276(41):38121-38. PMID: 11457855
Caveolin-1 is the principal structural protein of caveolae membranes in fibroblasts and endothelia. Recently, we have shown that the human CAV-1 gene is localized to a suspected tumor suppressor locus,...
8.
Lee H, Woodman S, Engelman J, Volonte D, Galbiati F, Kaufman H, et al.
J Biol Chem . 2001 Jul; 276(37):35150-8. PMID: 11451957
Caveolin-1 was initially identified as a phosphoprotein in Rous sarcoma virus-transformed cells. Previous studies have shown that caveolin-1 is phosphorylated on tyrosine 14 by c-Src and that lipid modification of...
9.
Galbiati F, Engelman J, Volonte D, Zhang X, Minetti C, Li M, et al.
J Biol Chem . 2001 Mar; 276(24):21425-33. PMID: 11259414
Caveolin-3, a muscle-specific caveolin-related protein, is the principal structural protein of caveolae membrane domains in striated muscle cells. Recently, we identified a novel autosomal dominant form of limb-girdle muscular dystrophy...
10.
Engelman J, Berg A, Lewis R, Lisanti M, Scherer P
Mol Endocrinol . 2000 Oct; 14(10):1557-69. PMID: 11043572
Tumor necrosis factor-alpha (TNFalpha) has been implicated as a contributing mediator of insulin resistance observed in pathophysiological conditions such as obesity, cancer-induced cachexia, and bacterial infections. Previous studies have demonstrated...